it warning June 26th), leaves outlook unchanged (trading +1.5%) Merck Q2 good beat across the board helped by FX, raising guidance (trading +4.2%) Celesio Q2 inline across the board, maintains full year guidance (trading +4.5%) GFK Q2 below consensus, sales and net light, confirms FY guidance (trading -6.